Home » Posts tagged with » pharma acquisition news
AbbVie wraps up $63bn acquisition of Irish drugmaker Allergan

AbbVie wraps up $63bn acquisition of Irish drugmaker Allergan

US biopharma company AbbVie has wrapped up its previously announced $63 billion acquisition of Irish drugmaker Allergan following receipt of all the required approvals from all government authorities and approval from the Irish High Court. AbbVie acquisition of Allergan, which was announced in June 2019, is said to expand and diversify significantly the former’s revenue […]

AbbVie acquisition of Allergan gets antitrust clearance from US FTC

AbbVie acquisition of Allergan update : US biopharma company AbbVie has secured clearance from the US Federal Trade Commission (FTC) for its previously announced $63 billion acquisition of Botox developer Allergan. According to AbbVie, the approval from the FTC satisfies all the necessary antitrust clearances required for the closing of the cash cum stock deal […]

Continue reading …
Alexion Pharmaceuticals to acquire Portola Pharmaceuticals for $1.4bn

Alexion acquisition of Portola : Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals, a commercial-stage biopharma company focused on life-threatening blood-related disorders, for $1.41 billion. Portola Pharmaceuticals developed Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], which is marketed as Ondexxya in Europe. The drug is the first and only approved Factor Xa inhibitor reversal agent, and […]

Continue reading …
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven

Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been acquired by the US biotech company for $95.50 per share in cash to become the latter’s fully-owned subsidiary. Forty Seven will be delisted from the Nasdaq Global Select Market. The […]

Continue reading …
Japanese group AGC offers €240m bid for Italian biotech company Molmed

Japanese conglomerate AGC has offered a takeover bid of €240 million to acquire 100% of Italian biotech company cum contract development and manufacturing organization (CDMO) Molecular Medicine (Molmed), valuing the latter at €0.518 per share. The clinical-stage Italian biotech company is engaged in research, development, manufacturing and also clinical validation of gene and cell therapies. […]

Continue reading …
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]

Continue reading …
PCI acquires Canadian pharma packaging company Bellwyck Pharma Services

PCI Pharma Services, a pharma supply chain solutions provider, has acquired Canada-based pharma packaging company Bellwyck Pharma Services for an undisclosed price. Bellwyck Pharma Services has been serving the clinical trial and commercial drug markets with primary and secondary packaging and labeling for 25 years. Its acquisition will give four GMP-compliant facilities for PCI Pharma […]

Continue reading …
Towa Pharmaceutical acquires Pensa Investments from Esteve

Japanese pharma company Towa Pharmaceutical has wrapped up its previously announced €320 million acquisition of Pensa Investments – the generics division of Spanish pharma company Esteve, as per the latest pharma acquisition news. The deal also includes Breckenridge Pharmaceutical, a pharmaceutical marketing and distribution firm in the US, which is part of Pensa Investments. Announced […]

Continue reading …
Sorrento Therapeutics turns down $993m takeover bid from private equity firm

Sorrento Therapeutics, a California-based biopharma company, has turned down a takeover bid worth about $993 million from an undisclosed private equity fund, as per the latest pharma acquisition news. Earlier this month, the US biopharma company was offered $7.00 per share for the acquisition of a majority stake or 100% in the former. Sorrento Therapeutics […]

Continue reading …
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle

Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma acquisition news. Financial details of the two deals have not been disclosed. The divestments are being taken up in an effort to wrap up the $63 billion AbbVie acquisition of […]

Continue reading …
Page 1 of 512345